

July 21, 2020



Aptose to Release Second Quarter Ended June 30, 2020 Financial Results and Hold Conference Call on August 4, 2020

SAN DIEGO and TORONTO, July 21, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results for the quarter ended June 30, 2020, on Tuesday, August 4, 2020, after the close of the market.

Conference Call & Webcast:

Date: Tuesday, August 4, 2020
Time: 5:00 PM EDT
Dial In - Toll-Free: 1 844-882-7834
Dial In - International: 1 574-990-9707
Passcode: 8367033
Webcast: [LINK](#)

Replay available through August 11, 2020:

Dial In - Toll-Free: 1 855-859-2056
Dial In - International: 1 404-537-3406
Replay Passcode: 8367033

The live conference call can also be accessed through a link on the Investor Relations section of Aptose's website at <https://www.aptose.com/investors/news-events/ir-calendar>. An archived version of the webcast along with a transcript will be available on the company's website for 30 days.

The press release, the financial statements and the management's discussion and analysis for the quarter ended June 30, 2020 will be available on SEDAR at www.sedar.com and EDGAR at www.sec.gov/edgar.shtml.

About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products for hematologic malignancies: CG-806, an oral, first-in-class mutation-agnostic FLT3/BTK kinase inhibitor, is in a Phase 1 trial in patients with relapsed or

refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies, and has received an IND allowance to conduct a separate Phase 1 trial in patients with relapsed or refractory acute myeloid leukemia (AML); APTO-253, the only clinical stage agent that directly targets the MYC oncogene and suppresses its expression, is in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS).

For further information, please contact:

Aptose Biosciences Inc.

Greg Chow
Executive Vice President, CFO
650-718-5028
gchow@aptose.com

LifeSci Advisors, LLC

Dan Ferry, Managing Director
617-535-7746
Daniel@LifeSciAdvisors.com

SMP Communications

Susan Pietropaolo
201-923-2049
susan@smpcommunications.com



Source: Aptose Biosciences, Inc.